Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ...

Mainz Biomed (MYNZ) reviewed its major accomplishments for the year ended December 31, 2025. “I’m extremely pleased with the achievements of our ...

YD Bio entered a memorandum of understanding to merge with EG BioMed in a combination intended to advance DNA methylation-driven AI platforms for cancer diagnostics and drug development. The ...

Ltd announced that through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and offerings—supported by deals with Medtronic and Ligand Pharmaceuticals—as it looks to ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

SAN DIEGO--(BUSINESS WIRE)--BioMed Realty, a Blackstone portfolio company and leading provider of real estate solutions to the life science and technology industries, announced today that John Lee has ...

RICHMOND — Edison High School Biomed IV students put on their thinking caps and created ways to optimize emergency rooms ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...